Age-dependent prognostic effect by mitosis-karyorrhexis index in neuroblastoma: A report from the children's oncology group

Pediatric and Developmental Pathology

Volumn 17, Issue 6, 2014, Pages 441-449

  Teshiba, Risa ^a   Kawano, Shinya ^a   Wang, Larry L ^a   He, Lejian ^a   Naranjo, Arlene ^b   London, Wendy B ^c   Seeger, Robert C ^a   Gastier Foster, Julie M ^d   Look, A Thomas ^c   Hogarty, Michael D ^e   Cohn, Susan L ^f   Maris, John M ^e   Park, Julie R ^g   Shimada, Hiroyuki ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Age cut off; International Neuroblastoma Pathology Classification; Mitosis karyorrhexis index; Neuroblastoma; Prognosis

Indexed keywords

AGE; ARTICLE; ASSESSMENT OF HUMANS; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; EVENT FREE SURVIVAL; HUMAN; INTERMEDIATE RISK POPULATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MITOSIS KARYORRHEXIS INDEX; NEUROBLASTOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION; BIOPSY; CANCER STAGING; CHI SQUARE DISTRIBUTION; DISEASE COURSE; DISEASE FREE SURVIVAL; GENE AMPLIFICATION; GENETICS; INFANT; KAPLAN MEIER METHOD; KARYOTYPING; MITOSIS; MITOSIS INDEX; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; PREDICTIVE VALUE; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; TIME FACTOR;

MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

AGE FACTORS; BIOPSY; CHI-SQUARE DISTRIBUTION; CHILD, PRESCHOOL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GENE AMPLIFICATION; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; KARYOTYPING; MITOSIS; MITOTIC INDEX; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS;

EID: 84920949954     PISSN: 10935266     EISSN: 16155742     Source Type: Journal    
DOI: 10.2350/14-06-1505-OA.1     Document Type: Article

References (33)

1. Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL. Infant cancer in the US: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 1997;19:428-432.
2. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J Clin Oncol 2009;27:289-297.
3. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma: Children's Cancer Study Group A. Cancer 1971;27:374-378.
4. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HW. Prognostic factors in neuroblastoma. Cancer 1987;59:1853-1859.
5. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874-1881.
6. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for Neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
7. Shimada H, Chatten J, Newton WA, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405-416.
8. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: Recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349-363.
9. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada System). Cancer 1999;86:364-372.
10. Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors. Cancer 2001;92:2451-2461.
11. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-1116.
12. Shimada H, Stram DO, Chatten J, et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995;87:1470-1476.
13. Oppedal BR, Storm-Mathisen I, Lie SO, Brandtzaeg P. Prognostic factors in neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis. Cancer 1988;62:772-780.
14. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311: 231-235.
15. Fong CT, White PS, Peterson K, et al. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res 1992;52:1780-1785.
16. Attiyeh EF, London WB, Mossé YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353: 2243-2253.
17. Peuchmaur M, d'Amore ES, Joshi VV, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003;98:2274-2281.
18. Shimada H, Nakagawa A, Peters J, et al. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance. Cancer 2004;101:1873-1881.
19. Suzuki T, Bogenmann E, Shimada H, Stram D, Seeger RC. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993;85:377-384.
20. Goto S, Umehara S, Gerbing RB, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92:2699-2708.
21. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
22. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II: analysis and examples. Br J Cancer 1977;35:1-39.
23. Umehara S, Nakagawa A, Matthay KK, et al. Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular. Cancer 2000;89:1150-1161.
24. Baudino TA, Cleveland JL. The Max network gone mad. Mol Cell Biol 2001;21:691-702.
25. Stanton BR, Perkins AS, Tessarollo L, Sassoon DA, Parada LF. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev 1992;6:2235-2247.
26. Mugrauer G, Alt FW, Ekblom P. N-myc proto-oncogene expression during organogenesis in the developing mouse as revealed by in situ hybridization. J Cell Biol 1988;107:1325-1335.
27. Charron J, Malynn BA, Fisher P, et al. Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. Genes Dev 1992;6:2248-2257.
28. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991;251:1211-1217.
29. Knoepfler PS, Cheng PF, Eisenman RN. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 2002;16: 2699-2712.
30. Greer C, Lee M, Westerhof M, et al. Myc-dependent genome instability and lifespan in Drosophila. PloS one 2013;8:e74641.
31. Schwab M, Corvi R, Amler LC. N-MYC oncogene amplification: a consequence of genomic instability in human neuroblastoma. Neuroscientist 1995;1:277-285.
32. Suganuma R, Wang LL, Sano H, et al. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatr Blood Cancer 2013;60:363-370.
33. Wang LL, Suganuma R, Ikegaki N, et al. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. Cancer 2013;119:3718-3726.